









Markets
/
Stocks
/
nasdaq-iqv
/

IQVIA Holdings Inc

IQV



View Detailed Chart

222.260USD

-3.730-1.65%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

37.85BMarket Cap

30.30P/E TTM



IQVIA Holdings Inc

222.260

-3.730-1.65%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.65%

5 Days

-1.59%

1 Month

-0.58%

6 Months

+41.67%

Year to Date

+13.10%

1 Year

+11.65%

View Detailed Chart

TradingKey Stock Score of IQVIA Holdings Inc

Currency: USD Updated: 2025-12-12

Key Insights

IQVIA Holdings Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 7/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 249.55.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IQVIA Holdings Inc's Score

Industry at a Glance

Industry Ranking

7 / 404

Overall Ranking

55 / 4592

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Buy

Current Rating

249.550

Target Price

+11.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

IQVIA Holdings Inc Highlights

StrengthsRisks

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 15.40B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 15.40B.

Fairly Valued

The company’s latest PE is 30.30, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 175.98M shares, decreasing 0.47% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 2.79K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.